 Home > Medical News > Latest Medical News > Lybalvi launches in the U.S. to treat schizophrenia and bipolar I disorder

Lybalvi launches in the U.S. to treat schizophrenia and bipolar I disorder

 Last Update: 2021-11-16
 Source: Internet
 Author: User

Tags

unipolar depressive disorder

seed treatment

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Recently, Alkermes announced the launch of Lybalvi (olanzapine/samidorphan) in the US market, which is a new, once-daily atypical antipsychotic for the treatment of: (1) adult patients with schizophrenia; (2) biphasic Adult patients with type I disorder

Lybalvi was approved by the US FDA for the above two indications at the end of May this year

Lybalvi is a two-layer tablet made from a marketed antipsychotic drug olanzapine and a novel new molecular entity samidorphan (a novel selective μ-opioid receptor antagonist)

Schizophrenia and bipolar I disorder are complex chronic diseases, and safe and effective new drugs are still needed

In the ENLIGHTEN clinical development project, Lybalvi demonstrated the antipsychotic efficacy, safety, and tolerability, including the weight gain of schizophrenia patients who received Lybalvi treatment in the ENLIGHTEN-2 study was statistically significantly lower than the olanzapine treatment group

The FDA approved Lybalvi through the 505(b)(2) regulatory pathway.

ENLIGHTEN-1 is a 4-week randomized, double-blind phase III study in patients with schizophrenia who are experiencing acute exacerbations.

ENLIGHTEN-2 is a 6-month book, double-blind phase III study conducted in patients with stable schizophrenia to evaluate the effects of Lybalvi and placebo on body weight

Note: The original text has been deleted

Original source: Alkermes Announces Commercial Availability of LYBALVI® for the Treatment of Schizophrenia and Bipolar I Disorder

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.